5 years ago, the WHO declared COVID a pandemic. Here's a look at the disease by the numbers
Tuesday marks five years since the World Health Organization (WHO) declared the global outbreak of COVID-19 to be a pandemic.
Since then, millions of Americans have been hospitalized, and more than 1.2 million people have died.
Additionally, millions of adults and children are still feeling the effects of their illness and have been diagnosed with long COVID.
Here's a look at the disease in the U.S. by the numbers.
MORE: New coronavirus found in bats is not currently 'concern to public health': CDC
In the last 28 days, ending about Feb. 16, 2025, about 3,800 Americans were hospitalized due to COVID-19, according to data from the WHO.
During the week ending Feb. 22, the most recent week for which data is available, data from the Centers for Disease Control and Prevention (CDC) shows that just 1.3% of inpatient beds were occupied by COVID-19 patients as well as 1.3% of intensive care unit beds.
Additionally, during the week ending March 1, the rate of COVID-19-associated hospitalizations was 1.4 per 100,000 people. The peak for the 2024-25 season was 4.2 per 100,000 people during the week ending Jan. 4, which is much lower than the peak of 35.6 per 100,000 people during the 2021-22 season.
Since the pandemic began, more than 1.22 million Americans have died from COVID-19 as of March 6, 2025, according to the latest CDC data. The U.S. crossed the 1 million mark on May 12, 2022.
During the week ending March 1, there were 274 deaths recorded from COVID, according to CDC provisional data. This is the lowest number recorded since the pandemic began.
Meanwhile, the age-adjusted death rate currently sits at 0.1 per 100,000 people, which has remained relatively consistent since spring 2024 and is among the lowest rates recorded since the pandemic.
By comparison, during the height of the omicron wave in winter 2021-22, the death rate was 53 times higher at 5.3 per 100,000. The highest-ever death rate was recorded the week ending Jan. 9, 2021, at 6.5 per 100,000.
Studies have suggested COVID-19 vaccines, combined with mitigation measures, helped save hundreds of thousands of lives in the U.S.
Long COVID is a condition that occurs when someone infected with COVID-19 is within three months of the initial diagnosis and lasts at least two months.
As of August 2024, a federal survey found that 17.9% of adults have experienced long COVID -- equivalent to about 47.6 million Americans, according to 2024 U.S. Census Bureau estimates.
MORE: Trump bars federal funding to schools with COVID vaccine mandates
Meanwhile, 5.3% of adults -- equivalent to about 14.1 million Americans -- reported they were currently experiencing long COVID symptoms at the time of the survey. Of those currently experiencing long COVID, nearly a quarter said they had significant activity limitations.
Another recent federal study, published in the journal JAMA Pediatrics in February, showed approximately 1.01 million children, or 1.4%, are believed to have ever experienced long COVID as of 2023 and about 293,000, or 0.4%, were experiencing the condition when the survey was being conducted.
In June 2024, the CDC recommended that everyone ages 6 months and older receive an updated 2024-2025 COVID-19 vaccine to protect against severe illness, hospitalization and death.
The updated vaccines target the JN.1 lineage of the virus, an offshoot of the omicron variant. There are formulations from Pfizer-BioNTech and Moderna available for those 6 months old and older and from Novavax available for those aged 12 and older.
The CDC, however, has previously stated vaccination coverage remains low, meaning "many children and adults lack protection from respiratory virus infections provided by vaccines."
As of Feb. 22, 2025, only 23.2% of adults and 11.9% of children were vaccinated with the updated vaccine, CDC data shows.
Additionally, despite evidence showing the vaccine is safe for pregnant women, the CDC estimates that just 13.8% of pregnant women have received the updated vaccine.
5 years ago, the WHO declared COVID a pandemic. Here's a look at the disease by the numbers originally appeared on abcnews.go.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Trump's DOGE efficiency agency says it slashes $25B in federal spending as rehiring begins
The Department of Government Efficiency (DOGE) announced on Wednesday it has decreased its annual non-defense federal obligations by an additional ~1.9% since last month. As of June 8th, annual non-defense federal obligations are down 22.4%, or ~$25B, as compared to 2024, DOGE announced on X. The cut marks an additional ~1.9% reduction from last month's figures, which were announced on May 8. Doge's Greatest Hits: Look Back At The Department's Most High-profile Cuts During Trump's First 100 Days "Cash outlays will follow as obligations come due," DOGE wrote in the post. "Our initiative to reduce wasteful spend, consistent with the DOGE Cost Efficiency Executive Order, continues to bear fruit." On May 14, DOGE announced the current year's non-defense federal obligations were down 20.5% as compared to 2024. Read On The Fox News App The announcement came minutes before Fox News Digital was first to report the Department of Health and Human Services (HHS) is rehiring more than 450 previously fired employees belonging to multiple divisions within the agency's Centers for Disease Control and Prevention (CDC). The rehired CDC employees came from the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention; the National Center for Environmental Health; the Immediate Office of the Director, and the Global Health Center, according to an HHS official familiar with the matter. HHS Secretary Robert F. Kennedy Jr. told CBS News in April some personnel who were cut shouldn't have been. Doge Ends 108 'Wasteful' Contracts, Including For An 'Executive Transformational Leadership Training Program' "We're reinstating them, and that was always the plan," Kennedy said. "Part of the—at DOGE, we talked about this from the beginning, is we're going to do 80% cuts, but 20% of those are going to have to be reinstated, because we'll make mistakes." In addition to the HHS rehires, the Internal Revenue Service, Food and Drug Administration, State Department, and Department of Housing and Urban Development started rehiring employees let go during DOGE cuts, the Washington Post reported. Doge Takes A Chainsaw To Federal Spending With 7 Major Victories This Week: 'Got To Be Done' Another roadblock this week was a ruling from U.S. District Judge Denise Cote of the Southern District of New York, who ruled to restrict the agency's access to federal databases. The Trump administration previously said DOGE could not work effectively with the limitations, noting DOGE needed to access Social Security information to root out fraud. Fox News Digital's Alec Schemmel and Danielle Wallace contributed to this article source: Trump's DOGE efficiency agency says it slashes $25B in federal spending as rehiring begins
Yahoo
42 minutes ago
- Yahoo
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data